WO2003011329A2 - Impfstoff für veterinäre und humanmedizinische prophylaxe und therapie von dermatophytosen - Google Patents
Impfstoff für veterinäre und humanmedizinische prophylaxe und therapie von dermatophytosen Download PDFInfo
- Publication number
- WO2003011329A2 WO2003011329A2 PCT/EP2002/008435 EP0208435W WO03011329A2 WO 2003011329 A2 WO2003011329 A2 WO 2003011329A2 EP 0208435 W EP0208435 W EP 0208435W WO 03011329 A2 WO03011329 A2 WO 03011329A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- strains
- ccm
- vaccination
- vaccination strains
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
Definitions
- the present invention relates to a new vaccine containing vaccination strains of dermatophytes, its use for
- the vaccines according to the invention can be used in both veterinary and human medicine
- a number of vaccines are currently used in veterinary medicine both prophylactically and therapeutically against dermatophytoses. These are both live vaccines and inactivated vaccines. They are described in CS 160324, PL 156844, SU 1734762, GB 2025222, SU 955570, SU 955571, SU 548947, SU 835446, RU 2013444, RU 2013445, EP 393371, DE 9218921 U1, PL 100958, US 4,229,434, US 5,277,904, among others. US 5,284,652, CS 201481, CS 246791, CS 261460, CZ 279278 and CZ 279982.
- the present invention first relates to a new vaccine containing vaccination strains of dermatophytes, its use for
- the vaccines according to the invention are used both in human and in veterinary medicine.
- the warm-blooded animals to be treated according to the invention in veterinary medicine include, in particular, domestic and farm animals.
- dermatophytosis means a disease of the skin and its appendages caused by dermatophytes.
- the invention relates to a vaccine containing at least one dermatophyton vaccination strain.
- Dermatophytes include fungi of the genera Trichophyton, Microsporum, Epidermophyton, Arthroderma and Nannizzia.
- Particularly preferred vaccination strains belong to the genus Trichophyton, in particular the strains Trichophyton verrucosum CCM F-765 (a1), Trichophyton verrucosum CCM 8166 (a2), Trichophyton mentagrophytes CCM 8290 (a3) and Trichophyton rubrum CCM 8291 (a).
- Trichophyton verrucosum CCM F-765 (a1) and Trichophyton verrucosum CCM 8166 (a2) strains were originally filed by applicants to the Czech Collection of Microorganism (CCM), Masaryk University, Tvrdeho 14, 602 00 Brno on November 5, 1984 respectively on February 23, 1993 under the deposit numbers CCM F-765 and CCM 8166, these deposits were converted on December 14, 1992 and July 22, 2002 into deposits under the Budapest Treaty.
- Cultures of the above-mentioned strains Trichophyton mentagrophytes CCM 8290 (a3) and Trichophyton rubrum CCM 8291 (a4) were deposited there on July 23, 2001 under the Budapest Treaty under the deposit numbers CCM 8290 and CCM 8291, respectively.
- a further preferred embodiment is a vaccine which contains a combination of at least two of the vaccination strains of the genus Trichophyton listed above; a combination of three of the four vaccination strains listed above is very particularly preferred.
- a ratio of the individual vaccination strains a1: a2: a3: a4 of 0 or 2-10: 0 or 1-5: 0 or 5-30: 0 or 2-10, or of 0 or 1-10: 0 or 1-2: 0 or 3-30: 0 or 1-3, or of 0 or 1-10: 0 or 1 ⁇ : 0 or 3-30: 0 or 1-10 in the end product is particularly preferred.
- Embodiments with the ratio a1: a2: a3 of 2: 1: 5 or 10: 1: 30 or the sole use of a1 are very particularly preferred for veterinary use.
- Embodiments with the ratio a1: a2: a3: a4 of 4: 2: 10: 3 or 10: 1: 30: 2 and the ratios a1: a3: a4 of 1: 3 are very particularly preferred for human use. 1 and a2: a4 of 1: 2 or the sole use of a4 (Trichophyton rubrum CCM 8291).
- the total number of vegetative forms of the vaccination strains in the end product is at least 1 million per 1 ml.
- a total number of at least 5 million per 1 ml is particularly preferred, very particularly preferably at least 10 million per 1 ml.
- the pH range of the end product is pH 3.0 to 10.0.
- Suitable buffer systems that are generally known to the person skilled in the art, such as Acetate or carbonate buffer systems or pharmaceutically acceptable organic or inorganic acids such as citric acid, acetic acid or hydrochloric acid are used.
- the preferred pH range is pH 6.0 to 8.0. To do this. Phosphate buffer systems of different compositions are used which are generally known to the person skilled in the art.
- the total formaldehyde content is 0.02% or less for human medical purposes and 0.05% or less for veterinary purposes. This amount remaining after inactivation is physiologically safe and legally permitted. It also has a disinfectant and prophylactic and therapeutic effect. If necessary, the formaldehyde can be supplemented or substituted by other substances. In addition to the particularly suitable formaldehyde, chemical measures or physical applications can be used, such as beta-propionolactone, binary ethyleneimine and acetic acid.
- a total content of less than 0.02% or 0.05% formaldehyde is very particularly preferred.
- the vaccines according to the invention can be administered parenterally, e.g. can be administered intramuscularly or subcutaneously or also epicutaneously.
- Epicutaneous application ie, is particularly preferred for human medical use. the application and distribution on the skin.
- epicutaneous application in the toe area the main source of skin mycoses of other parts of the body in humans, is preferred.
- epicutaneous application can minimize the risk of potentially life-threatening anaphylactic or anaphylactoid reactions.
- the epicutaneous route of administration also has other advantages, since no injection is necessary, as is the case with the otherwise usual parenteral administration of vaccines. Due to the absence of pain or the lower fear of expectation, patient compliance is better, this also applies to veterinary medicine, of course, since no dangerous fear / pain reaction of the animals is to be expected for the treating person.
- Another aspect of the invention is the provision of a production method for the vaccine against dermatophytoses according to the invention as described below:
- the vaccination strains are individually grown on saccharide- and organically bound nitrogen-containing agar soils of suitable composition as nutrient media, if necessary after an intermediate adjustment of the pH, at temperatures in the range from 25 to 29 ° C. under sterile conditions for a period of 10 to 30 Days increased until the optimal formation of vegetative forms.
- the strains are then homogenized in an aqueous 0.1% formaldehyde solution and the suspensions formed are inactivated at a temperature of 18-26 ° C. for at least 24 to 36 hours. The homogenization takes place in such a way that the majority of the spores are separated from the mycelium without destroying their surface structure.
- the individual strains are mixed with one another, if necessary, and supplemented with a phosphate or, if appropriate, buffered physiological saline solution in such a way that the total number of vegetative forms of all vaccination strains is at least 1 million per 1 ml, preferably at least 5 million per 1 ml of vaccine, the pH is between pH 3 and pH 10, preferably between 6.0 - 8.0 and the formaldehyde content remaining after inactivation is 0.02% or less in a human medical application and in a veterinary application Is 0.05% and less.
- the mixture of the strains a1: a2: a3: a4 corresponds to the ratio of 0 or 2-10: 0 or 1-5: 0 or 5-30: 0 or 2-10 in the end product, the abovementioned Mixing ratios and individual strains are particularly preferred.
- the antigenic composition of the vaccine according to the invention is so wide that immune reactions against homologous genera and cross-reactions against other dermatophyte genera such as e.g. Microsporum canis or Trichophyton equinum have been detected.
- Example 1 Preparation of a veterinary vaccine and application
- a culture medium containing 1.2% agar, -5.0% saccharides and 0.3% organically bound nitrogen was used to grow / multiply the vaccination strains of the genus Trichophyton.
- the nutrient medium was sterilized in a steam autoclave for 20 to 30 minutes at a pressure of 80 to 100 kPa. After the pH was adjusted to 6.0 to 7.0, the bottom of the glass flask was covered with the nutrient medium and the sterilization was repeated under the above conditions. After the agar had solidified and the sterility had been checked, the culture flasks were individually inoculated with suspensions of the vaccination strains. Either lyophilisates or freshly prepared inocula from the vaccination strains (CCM F-765, CCM 8166 and CCM 8290) were used for the inoculation. Each inoculum contained at least 0.5 million viable CFUs per 1 ml.
- the inocula of the vaccination strains were distributed on the surface of the nutrient medium.
- the cultivation took place at a temperature of 25 to 29 ° C for 10 to 30 days in order to achieve an optimal formation of vegetative forms.
- the grown cultures were removed at the stage of a high productivity of the fungal antigen from the surface of the nutrient medium and homogenized in an aqueous 0.1% 'strength by weight formaldehyde solution.
- the homogenization with the homogenizer takes place in such a way that the majority of the spores are separated from the mycelium without destroying their surface structure.
- the resulting homogeneous suspension was individually aliquoted into storage vessels and stored at a temperature of 18 to 26 ° C for 24 hours to inactivate the vaccination strains.
- the number of vegetative forms for the individual vaccination strains was then determined in a Bürker counting chamber. It totaled 41 million in 1 ml vaccine.
- the individual vaccination strains were mixed so that a ratio of Trichophyton verrucosum CCM F-765 in the finished vaccine preparation: Trichophyton verrucosum CCM 8166: Trichophyton mentagrophytes CCM 8290 of 2: 1: 5 was present.
- the formaldehyde content was 0.05%.
- the pH of the preparation was adjusted to pH 6.0 by adding phosphate-buffered physiological saline.
- the vaccine thus produced was checked for sterility and number of vegetative forms and used to vaccinate cattle infected with trichophytosis. After two intramuscular inoculations in a dose of 5 ml each, the disease in cattle from two breeds cured within 14 days after the revaccination.
- a culture medium with an agar content of 1.3%, a saccharide content of 10.0% and a content of organically bound nitrogen of 0.5% was used to grow the vaccination strain.
- the sterilization was carried out in a steam autoclave twice for 30 minutes at an overpressure of 120 kPa.
- the pH of the nutrient medium was 6.6. This was inoculated with a suspension of the Trichophyton verrucosum GCM F-765 strain, and the cultivation temperature was kept at 25-26 ° C.
- the culture was homogenized in a 0.1% formaldehyde solution after 15 days of cultivation. After 36 hours of inactivation at a temperature of 22 ° C, phosphate-buffered saline was added.
- the formaldehyde content in the finished vaccine solution was 0.04%, the pH 7.3 and the number of vegetative forms of the vaccination strain 22 million in 1 ml.
- Example 3 Preparation of a veterinary vaccine and application
- Example 2 The procedure was similar to that in Example 1, the strains T. verrucosum CCM F-765, T. verrucosum CCM 8166 and T. mentagrophytes CCM 8290 were in a ratio of 10: 1: 30.
- the formaldehyde content was 0.04%
- the pH was adjusted to 8.0
- the total number of vegetative forms of all vaccination strains was 80.0 million in 1 ml of vaccine.
- the vaccine solution was tested for tolerance on calves 1 month of age. 10 ml of vaccine solution were inoculated into five calves intramuscularly in the gluteal muscles. At a time interval of 24 hours before vaccination, at the time of vaccination, 4 hours after vaccination and on the following 4 days, the calves' temperature was measured rectally. The vaccine was tolerated, the body temperatures remained in the range of the physiological values in all animals. No unwanted local or other after-effects were found in the vaccinated calves.
- Example 4 Preparation of a human medical vaccine and application
- the vaccination strains were propagated in a nutrient medium containing 1.5% agar, 15.0% saccharides and 1.0% organically bound nitrogen.
- the sterilization of the nutrient medium was carried out twice for 25 minutes in a steam autoclave at an excess pressure of 80 to 100 kPa. Inoculation, cultivation of the vaccination strains, homogenization, inactivation and determination of the number of vegetative forms were carried out in the same manner as described under 1 above.
- the vaccine strains Trichophyton verrucosum CCM F-765: Trichophyton rubrum CCM 8291: Trichophyton CCM mentagrophytes CCM 8290 were mixed in a ratio of 1: 1: 3.
- a suitable amount of phosphate-buffered physiological saline was added to the suspension obtained, resulting in a residual formaldehyde content of 0.02% and a total number of vegetative forms contained in the end product of 10 million.
- the pH was adjusted to between 6.0 and 8.0 depending on the composition of the buffer solution.
- the vaccine was checked for sterility and tested for harmlessness in humans on volunteers. For this purpose, the vaccine was applied three times a week in an amount of 10 ml by rubbing it into the intertropical skin on the lower extremities. No harmful side effects on humans have been identified.
- the vaccine was applied epicutaneously twice to cattle experimentally infected with trichophytosis. Compared to non-vaccinated animals, the healing success occurred about a week earlier, which demonstrates the therapeutic effectiveness of the vaccine according to the invention thus produced.
- Example 5 Production of a vaccine for human medical use
- the Trichophyton rubrum CCM 8291 vaccination strain was cultivated for 18 days at a temperature of 26-28 ° C. in a nutrient medium with a composition according to Example 2.
- the inactivation of the homogenized culture in a 0.1% formaldehyde solution at a temperature of 26 ° C took 24 hours.
- the pH was 6.8, the formaldehyde content was 0.015% and the number of vegetative forms of the vaccination strain was 11 million in 1 ml.
- a challenge test was carried out on the calf with the vaccine solution.
- the calves vaccinated twice epicutaneously were before an experimental trichophytic infection sufficiently protected, in contrast to the control animals not treated with vaccine.
- Example 6 Production of a vaccine for human medical use
- the vaccine solutions were prepared from different amounts of the two strains of dermatophytes Trichophyton verrucosum CCM F-765 and Trichophyton mentagrophytes CCM 8290.
- a culture medium containing 1.5% agar with 8.0% saccharides and 0.8% peptone was used to grow them.
- the sterilization was carried out twice in a steam sterilizer for 30 minutes at an overpressure of 120 kPa.
- the nutrient media were inoculated individually with the suspensions of the vaccination strains mentioned with a content of 1.0 million to 1 ml of inoculum. After 10 days of incubation at 25-27 ° C., the cultures were homogenized in a 0.1% formaldehyde solution at 10,000 revolutions per minute for a period of 2 to 3 minutes.
- the suspensions were then kept in the dark at 72 ° C. for 72 hours to inactivate the vaccination strains.
- the inactivation was demonstrated by means of an incubation test on the nutrient media.
- the inactivated suspension was diluted with a phosphate-buffered physiological saline so that the formaldehyde content assumed the value 0.018%, the pH 7.17 and the number of vegetative forms of the vaccination strains 15.8 million in 1 ml.
- Example 7 Production of a vaccine for human medical use
- the vaccination strains T. verrucosum CCM 8166 and T. rubrum CCM 8291 were grown on a culture medium with a composition of 1.2% agar, 10.0% saccharides and 0.5% peptone. These substances were sterilized in an autoclave in water under the same conditions as in Example 6. The cultivation at 28-29 ° C. was completed after 30 days, the cultures removed were homogenized in a 0.1% formaldehyde solution and inactivated at 24 ° C. for 24 hours. The ratio of the strains represented T. verrucosum CCM 8166 and T. rubrum CCM 8291 in the vaccine was 1: 2. The pH was adjusted between 6.0 and 8.0 by adding phosphate-buffered physiological saline solutions with different sodium hydrogen phosphate content. The number of vegetative forms was 5 million in 1 ml vaccine solution.
- the vaccine solution was epicutaneously applied to an area of 10 x 10 cm shaved and scarified skin of three calves in a volume of 5 ml per animal for three consecutive days. Neither local nor other post-vaccination reactions were observed in the animals.
- Example 8 Preparation of a human medical vaccine and application
- the nutrient medium was prepared according to example 2.
- the inoculation, cultivation and homogenization of the cultivated cultures was carried out analogously to Example 1.
- the total number of vegetative forms of the vaccination strains was 75 million in 1 ml, the formaldehyde content was 0.015%.
- the pH was adjusted between 6.0 and 8.0 by adding phosphate-buffered physiological saline solutions with different sodium hydrogen phosphate content
- the vaccine solution was tested on two volunteers with a volume of 2 ml epicutaneously in the area between the toes on 3 consecutive days.
- the vaccine was harmless and did not produce any undesirable clinical changes, either local or overall.
- Example 9 Preparation of a human medical vaccine and application
- the vaccine solution was applied therapeutically to affected areas in the area between the toes, as well as to the big toe of the left foot with clinical changes that suggest a mycosis; but failed to isolate the pathogen.
- the present invention thus provides a highly effective and also easy-to-administer vaccine for immunoprophylaxis and treatment of dermatophytoses in veterinary and human medicine.
- the vaccine according to the invention can be used in veterinary medicine both parenterally, in particular intramuscularly and subcutaneously, and epicutaneously.
- the vaccine according to the invention is in the Human medicine particularly preferably epicutaneously applicable by suitable application, such as by spraying with sterile spray ampoules onto human skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL02365029A PL365029A1 (en) | 2001-07-27 | 2002-07-29 | Novel vaccine for prophylaxis and therapy in veterinary and human medicine |
EP02767271A EP1411976A2 (de) | 2001-07-27 | 2002-07-29 | Impfstoff für veterinäre und humanmedizinische prophylaxe und therapie von dermatophytosen |
US10/480,406 US20040151726A1 (en) | 2001-07-27 | 2002-07-29 | Novel vaccine for prophylaxis and theraphy in vetirinary and human medicine |
JP2003516559A JP2004536146A (ja) | 2001-07-27 | 2002-07-29 | 獣医学およびヒト医学における予防および療法用の新規ワクチン |
CA002453831A CA2453831A1 (en) | 2001-07-27 | 2002-07-29 | Vaccine for prophylaxis and therapy of dermatophytosis in veterinary and human medicine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZPV2001-2732 | 2001-07-27 | ||
CZ20012732A CZ290509B6 (cs) | 2001-07-27 | 2001-07-27 | Vakcína proti dermatofytózám a způsob její výroby |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003011329A2 true WO2003011329A2 (de) | 2003-02-13 |
WO2003011329A3 WO2003011329A3 (de) | 2003-07-17 |
Family
ID=5473491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/008435 WO2003011329A2 (de) | 2001-07-27 | 2002-07-29 | Impfstoff für veterinäre und humanmedizinische prophylaxe und therapie von dermatophytosen |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040151726A1 (de) |
EP (1) | EP1411976A2 (de) |
JP (1) | JP2004536146A (de) |
CN (1) | CN1545417A (de) |
CA (1) | CA2453831A1 (de) |
CZ (1) | CZ290509B6 (de) |
PL (1) | PL365029A1 (de) |
RU (1) | RU2253467C1 (de) |
WO (1) | WO2003011329A2 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2560572C2 (ru) * | 2013-08-20 | 2015-08-20 | Федеральное государственное унитарное предприятие "Ставропольская биофабрика" | Способ производства вакцины для профилактики и терапии трихофитоза крупного рогатого скота |
CN112877217B (zh) * | 2020-12-10 | 2022-04-15 | 贵州大学 | 一种黄褐奈尼兹皮真菌菌株及其降解鸡毛中的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2025222A (en) * | 1978-06-07 | 1980-01-23 | Inst Experimentalnoi Veterinar | Vaccine for treatment of trichophytosis caused by trichophyton mentagrophytes |
EP0393371A1 (de) * | 1989-04-21 | 1990-10-24 | Jefferson Labs, Inc. | Impfstoff gegen Tinea |
WO1993007894A1 (de) * | 1991-10-21 | 1993-04-29 | Boehringer Ingelheim Vetmedica Gmbh | Dermatomykose-vakzine |
WO2001015725A1 (en) * | 1998-09-24 | 2001-03-08 | Alpharma As | Vaccine for the protection of a vertebrate animal against fungal skin infection |
-
2001
- 2001-07-27 CZ CZ20012732A patent/CZ290509B6/cs not_active IP Right Cessation
-
2002
- 2002-07-29 PL PL02365029A patent/PL365029A1/xx not_active Application Discontinuation
- 2002-07-29 JP JP2003516559A patent/JP2004536146A/ja not_active Withdrawn
- 2002-07-29 EP EP02767271A patent/EP1411976A2/de not_active Withdrawn
- 2002-07-29 RU RU2003137591/15A patent/RU2253467C1/ru not_active IP Right Cessation
- 2002-07-29 CA CA002453831A patent/CA2453831A1/en not_active Abandoned
- 2002-07-29 US US10/480,406 patent/US20040151726A1/en not_active Abandoned
- 2002-07-29 WO PCT/EP2002/008435 patent/WO2003011329A2/de not_active Application Discontinuation
- 2002-07-29 CN CNA028149149A patent/CN1545417A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2025222A (en) * | 1978-06-07 | 1980-01-23 | Inst Experimentalnoi Veterinar | Vaccine for treatment of trichophytosis caused by trichophyton mentagrophytes |
EP0393371A1 (de) * | 1989-04-21 | 1990-10-24 | Jefferson Labs, Inc. | Impfstoff gegen Tinea |
WO1993007894A1 (de) * | 1991-10-21 | 1993-04-29 | Boehringer Ingelheim Vetmedica Gmbh | Dermatomykose-vakzine |
WO2001015725A1 (en) * | 1998-09-24 | 2001-03-08 | Alpharma As | Vaccine for the protection of a vertebrate animal against fungal skin infection |
Also Published As
Publication number | Publication date |
---|---|
CZ20012732A3 (cs) | 2002-08-14 |
JP2004536146A (ja) | 2004-12-02 |
PL365029A1 (en) | 2004-12-27 |
CN1545417A (zh) | 2004-11-10 |
CZ290509B6 (cs) | 2002-08-14 |
US20040151726A1 (en) | 2004-08-05 |
EP1411976A2 (de) | 2004-04-28 |
CA2453831A1 (en) | 2003-02-13 |
WO2003011329A3 (de) | 2003-07-17 |
RU2003137591A (ru) | 2005-03-27 |
RU2253467C1 (ru) | 2005-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT408615B (de) | Neue influenzavirus-impfstoffzusammensetzung | |
DE69735191T2 (de) | Verfahren zur Herstellung multivalenter Impfstoffe | |
EP0304786A2 (de) | Intranasale Impfung von Pferden mit inaktivierten Mikroorganismen oder antigenem Material | |
DE69737067T2 (de) | Vakzine zur behandlung von mycosen | |
DE69021761T3 (de) | Impfstoff gegen Tinea. | |
DE2817299A1 (de) | Verfahren zur herstellung eines attenuierten infektioese-gastroenteritis (tge)-virusstammes zur anwendung in lebendvakzinen | |
DE2923144C2 (de) | Impfstoff zur Prophylaxe und Behandlung von durch Trichophyton mentagrophytes hervorgerufenen Trichophytien bei Pelztieren und Kaninchen und seine Herstellung | |
DE2423129A1 (de) | Verfahren zur herstellung temperaturempfindlicher, nicht pathogener mutantenstaemme von rinder-adeno-virusstaemmen und diese virusstaemme enthaltende lebendvakzine | |
EP0564620B1 (de) | Dermatomykose-vakzine | |
WO2003011329A2 (de) | Impfstoff für veterinäre und humanmedizinische prophylaxe und therapie von dermatophytosen | |
DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
DE2816942C2 (de) | Impfstoff gegen Rhinitis atrophicans beim Schwein | |
EP0445710A1 (de) | Verwendung von Zink-Calciumhydroxid, Lecithin und PAO zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen | |
EP2327420A2 (de) | Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens | |
DE2212277B2 (de) | Verfahren zur Herstellung einer Totvaccine gegen infektiöse atrophische Rhinitis der Schweine | |
DE3034238A1 (de) | Impfstoff zur bekaempfung der newcastle-krankheit und verfahren zur herstellung derselben | |
DE1792256C3 (de) | Oral applizierbare, polyvalente Impfstoffe gegen lokale Darminfektionen | |
DE60213785T2 (de) | Saponin inaktivierte mykoplasma impfstoffe | |
EP0642796A1 (de) | Salmonella-Lebendimpfstoff | |
DE2200376A1 (de) | Vaccine gegen Streptococcus equi. und Verfahren zu deren Herstellung | |
DE2415353A1 (de) | Verfahren zur herstellung von temperaturempfindlichen, nicht pathogenen mutanten von herpes simplex typ 2-viren und ihre verwendung zur herstellung von vaccinen | |
DE2602478B2 (de) | Impfstoff gegen die Panleukopenie . der Feliden | |
DE2167168C2 (de) | Flüssiges, Leberverdauungsbrühe, -extrakt oder -infusion enthaltendes Nährmedium zum anaeroben Züchten von Fusiformis nodosus und Verfahren zum anaeroben Züchten von Fusiformis nodusus | |
DE3345864A1 (de) | Impfstoff und verfahren zu seiner herstellung | |
Kielstein | Systematic control of dermatophytosis profunda of cattle in the former GDR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10480406 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12/MUMNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 32/MUMNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2453831 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002331357 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003516559 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028149149 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002767271 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002767271 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002767271 Country of ref document: EP |